Literature DB >> 26074686

Different treatment strategies and molecular features between right-sided and left-sided colon cancers.

Hong Shen1, Jiao Yang1, Qing Huang1, Meng-Jie Jiang1, Yi-Nuo Tan1, Jian-Fei Fu1, Li-Zhen Zhu1, Xue-Feng Fang1, Ying Yuan1.   

Abstract

The colon is derived from the embryological midgut and hindgut separately, with the right colon and left colon having different features with regards to both anatomical and physiological characteristics. Cancers located in the right and left colon are referred to as right colon cancer (RCC) and left colon cancer (LCC), respectively, based on their apparent anatomical positions. Increasing evidence supports the notion that not only are there differences in treatment strategies when dealing with RCC and LCC, but molecular features also vary between them, not to mention the distinguishing clinical manifestations. Disease-free survival after radical surgery of both RCC and LCC are similar. In the treatment of RCC, the benefit gained from adjuvant FOLFIRI chemotherapy is superior, or at least similar, to LCC, but inferior to LCC if FOLFOX regimen is applied. On the other hand, metastatic LCC exhibits longer survival than that of RCC in a palliative chemotherapy setting. For KRAS wild-type cancers, LCC benefits more from cetuximab treatment than RCC. Moreover, advanced LCC shows a higher sensitivity to bevacizumab treatment in comparison with advanced RCC. Significant varieties exist at the molecular level between RCC and LCC, which may serve as the cause of all apparent differences. With respect to carcinogenesis mechanisms, RCC is associated with known gene types, such as MMR, KRAS, BRAF, and miRNA-31, while LCC is associated with CIN, p53, NRAS, miRNA-146a, miRNA-147b, and miRNA-1288. Regarding protein expression, RCC is related to GNAS, NQO1, telomerase activity, P-PDH, and annexin A10, while LCC is related to Topo I, TS, and EGFR. In addition, separated pathways dominate progression to relapse in RCC and LCC. Therefore, RCC and LCC should be regarded as two heterogeneous entities, with this heterogeneity being used to stratify patients in order for them to have the optimal, current, and novel therapeutic strategies in clinical practice. Additional research is needed to uncover further differences between RCC and LCC.

Entities:  

Keywords:  Colon cancer; Left; Molecular; Right; Survival

Mesh:

Substances:

Year:  2015        PMID: 26074686      PMCID: PMC4458758          DOI: 10.3748/wjg.v21.i21.6470

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

1.  Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).

Authors:  Dominik P Modest; Christoph Schulz; Ludwig F von Weikersthal; Detlef Quietzsch; Jobst C von Einem; Andreas Schalhorn; Ursula Vehling-Kaiser; Rüdiger P Laubender; Clemens Giessen; Sebastian Stintzing; Volker Heinemann
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

2.  Risk factors associated with missed colorectal flat adenoma: a multicenter retrospective tandem colonoscopy study.

Authors:  Li Xiang; Qiang Zhan; Xin-Hua Zhao; Ya-Dong Wang; Sheng-Li An; Yang-Zhi Xu; Ai-Min Li; Wei Gong; Yang Bai; Fa-Chao Zhi; Si-De Liu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance.

Authors:  Vinod Gopalan; Suja Pillai; Faeza Ebrahimi; Ali Salajegheh; Tommy C Lam; Tran K Le; Nicole Langsford; Yik-Hong Ho; Robert A Smith; Alfred K-Y Lam
Journal:  Mol Carcinog       Date:  2013-09-05       Impact factor: 4.784

4.  Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.

Authors:  Jung Ho Kim; Ye-Young Rhee; Kyung-Ju Kim; Nam-Yun Cho; Hye Seung Lee; Gyeong Hoon Kang
Journal:  APMIS       Date:  2014-06-07       Impact factor: 3.205

5.  Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Authors:  H Blons; J F Emile; K Le Malicot; C Julié; A Zaanan; J Tabernero; E Mini; G Folprecht; J L Van Laethem; J Thaler; J Bridgewater; L Nørgård-Petersen; E Van Cutsem; C Lepage; M A Zawadi; R Salazar; P Laurent-Puig; J Taieb
Journal:  Ann Oncol       Date:  2014-10-06       Impact factor: 32.976

6.  Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?

Authors:  Timothy J Price; Carol Beeke; Shahid Ullah; Robert Padbury; Guy Maddern; David Roder; Amanda R Townsend; James Moore; Amitesh Roy; Yoko Tomita; Christos Karapetis
Journal:  Cancer       Date:  2014-11-06       Impact factor: 6.860

Review 7.  miRNA as markers for the diagnostic screening of colon cancer.

Authors:  Farid E Ahmed
Journal:  Expert Rev Anticancer Ther       Date:  2014-03-03       Impact factor: 4.512

8.  Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival.

Authors:  Frank Benedix; Rainer Kube; Frank Meyer; Uwe Schmidt; Ingo Gastinger; Hans Lippert
Journal:  Dis Colon Rectum       Date:  2010-01       Impact factor: 4.585

9.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

Authors:  Ludovic Barault; Céline Charon-Barra; Valérie Jooste; Mathilde Funes de la Vega; Laurent Martin; Patrick Roignot; Patrick Rat; Anne-Marie Bouvier; Pierre Laurent-Puig; Jean Faivre; Caroline Chapusot; Francoise Piard
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer.

Authors:  John M Carethers; Bhavya Murali; Bing Yang; Ryan T Doctolero; Akihiro Tajima; Ranor Basa; E Julieta Smith; Monte Lee; Ryan Janke; Tina Ngo; Ruth Tejada; Ming Ji; Matthew Kinseth; Betty L Cabrera; Katsumi Miyai; Temitope O Keku; Christopher F Martin; Joseph A Galanko; Robert S Sandler; Kathleen L McGuire
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

View more
  77 in total

1.  The prognostic relevance of primary tumor sidedness to surgical treatment for recurrent colon cancer.

Authors:  Tairin Uchino; Akira Ouchi; Koji Komori; Takashi Kinoshita; Taihei Oshiro; Tsuyoshi Sano; Yasuhiro Shimizu
Journal:  Surg Today       Date:  2020-06-28       Impact factor: 2.549

Review 2.  Colorectal Cancer: Why Does Side Matter?

Authors:  Claire Gallois; Simon Pernot; Aziz Zaanan; Julien Taieb
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

3.  Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer.

Authors:  Emily K Elizabeth McCracken; Gregory P Samsa; Deborah A Fisher; Norma E Farrow; Karenia Landa; Kevin N Shah; Dan G Blazer; Sabino Zani
Journal:  HPB (Oxford)       Date:  2019-05-30       Impact factor: 3.647

4.  D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer.

Authors:  Akira Watanabe; Kenichiro Araki; Norihumi Harimoto; Norio Kubo; Takamichi Igarashi; Norihiro Ishii; Takahiro Yamanaka; Kei Hagiwara; Hiroyuki Kuwano; Ken Shirabe
Journal:  Int J Clin Oncol       Date:  2018-03-24       Impact factor: 3.402

5.  KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013.

Authors:  Mary E Charlton; Amanda R Kahl; Alissa A Greenbaum; Jordan J Karlitz; Chi Lin; Charles F Lynch; Vivien W Chen
Journal:  J Natl Compr Canc Netw       Date:  2017-12       Impact factor: 11.908

6.  Impact of Colon Cancer Location on the Prognostic Significance of Nutritional Indexes and Inflammatory Markers.

Authors:  Tamuro Hayama; Tsuyoshi Ozawa; Kentaro Asako; Rie Kondo; Kohei Ono; Yuka Okada; Mitsuo Tsukamoto; Yoshihisa Fukushima; Ryu Shimada; Keijiro Nozawa; Keiji Matsuda; Shoichi Fujii; Takeo Fukagawa; Yojiro Hashiguchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

7.  Risk and prognostic nomograms for colorectal neuroendocrine neoplasm with liver metastasis: a population-based study.

Authors:  Xueliang Ding; Shaobo Tian; Jia Hu; Guobin Wang; Xiangnan Yu; Daan Fu; Ye Yuan; Lin Wang; Zheng Wang
Journal:  Int J Colorectal Dis       Date:  2021-06-01       Impact factor: 2.571

8.  Long-term Results of Surgery for Colorectal Liver Metastases in Terms of Primary Tumour Location and Clinical Risk Factors.

Authors:  Vladislav Treska; Martin Skala; Kristyna Prochazkova; Aneta Svejdova; Tereza Petrakova; Jakub Sebek; Ivan Riha; Jachym Rosendorf; Robert Polak; Tomas Skalicky; Vaclav Liska
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 9.  Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications.

Authors:  Petros Christakis Papagiorgis
Journal:  Tumour Biol       Date:  2016-02-03

10.  Tumor location impact in stage II and III colon cancer: epidemiological and outcome evaluation.

Authors:  Nesrine Mejri; Manel Dridi; Houda El Benna; Soumaya Labidi; Nouha Daoud; Hamouda Boussen
Journal:  J Gastrointest Oncol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.